We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
The meeting of the Advisory Committee on Vaccines (ACV).
The committee provided advice on two applications:
- major variation (change to dose regimen) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Comirnaty; active ingredient Tozinameran; sponsor Pfizer Australia Pty Ltd) that had been under evaluation from October 2021
- major variation (change to dose regimen) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Vaxzevria; active ingredient ChAdOx-1-S; sponsor AstraZeneca Pty Ltd) that had been under evaluation from November 2021.
Members
Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.